1877 — Shanghai Junshi Biosciences Co Balance Sheet
0.000.00%
- HK$27.02bn
- HK$28.87bn
- CNY2.50bn
Annual balance sheet for Shanghai Junshi Biosciences Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 3,505 | 6,000 | 3,779 | 2,917 | 3,195 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,455 | 344 | 991 | 565 | 522 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5,845 | 7,216 | 5,571 | 4,284 | 4,458 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,153 | 3,297 | 3,896 | 4,377 | 4,999 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 11,035 | 12,558 | 11,343 | 10,782 | 12,382 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,001 | 1,766 | 2,438 | 2,494 | 2,778 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3,090 | 3,075 | 4,192 | 4,922 | 6,352 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 7,945 | 9,484 | 7,151 | 5,860 | 6,030 |
| Total Liabilities & Shareholders' Equity | 11,035 | 12,558 | 11,343 | 10,782 | 12,382 |
| Total Common Shares Outstanding |